America's overdose crisis shows sustained decline

Overview

For the first time since 2018, American overdose deaths are falling—and they've kept falling for more than two years. CDC provisional data through August 2025 shows approximately 72,800 overdose deaths in the preceding 12 months, a 21% decline from the previous period. Deaths peaked at 112,000 in 2022. The drop represents roughly 80 lives saved per day compared to the crisis peak.

What's driving the decline remains contested. Researchers point to expanded naloxone access after FDA approved over-the-counter sales in 2023, the elimination of prescribing barriers for addiction medication, billions in opioid settlement funds flowing to communities, and possible disruptions to fentanyl precursor supply from China. But the progress is uneven: five states still saw increases, racial disparities persist, and roughly 73,000 annual deaths remains catastrophic by historical standards.

Play on this story Voices Debate Predict

Key Indicators

72,836

Predicted annual overdose deaths

CDC provisional estimate for 12 months ending August 2025

21%

Year-over-year decline

Continued decrease following 27% drop in 2024

112,109

2022 peak deaths

Highest annual overdose toll in U.S. history

$56B

Settlement funds allocated

Total awarded to states and localities from opioid lawsuits

States with declining deaths

Five states—Alaska, Montana, Nevada, South Dakota, Utah—saw increases

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

People Involved

Rahul Gupta

Left ONDCP January 2025; joined GATC Health as President

Anne Milgram

Leading federal enforcement against fentanyl trafficking

Organizations Involved

Centers for Disease Control and Prevention (CDC)

Federal Agency

Primary source for overdose mortality data

Federal agency tracking overdose deaths through the National Vital Statistics System, providing provisional monthly data used to measure crisis trends.

Office of National Drug Control Policy

Executive Office of the President

Coordinating federal drug policy under new administration

White House office coordinating the $44 billion federal drug budget across 19 agencies and setting national drug control priorities.

Timeline

CDC Reports 21% Decline Through August 2025
Data Release

New provisional data predicts 72,836 overdose deaths for 12 months ending August 2025. Decline continues for second consecutive year, though rate of decrease has slowed. Deaths down in 45 states.
January 14th, 2026
$7.4 Billion Purdue/Sackler Settlement Finalized
Legal

New York AG announces landmark settlement with Purdue Pharma and Sackler family. Sacklers pay up to $6.5 billion over 15 years; Purdue contributes $900 million. Largest individual opioid settlement.
January 14th, 2025
CDC Reports 27% Annual Decline—Largest Ever
Data Release

Provisional data shows approximately 80,000 deaths in 12 months ending early 2024, down from 110,000 the previous year. Largest single-year reduction in overdose deaths ever recorded.
May 14th, 2024
Biden-Xi Summit Revives Fentanyl Cooperation
Diplomatic

U.S. and China agree to resume counternarcotics cooperation frozen since 2019. China shuts down some precursor suppliers and resumes sharing suspicious shipment data with international authorities.
November 15th, 2023
Overdose Deaths Begin Sustained Decline
Turning Point

CDC data identifies August 2023 as inflection point when national overdose death rates reversed course. Deaths decline for 15 consecutive months—the longest sustained drop in decades.
August 1st, 2023
White House Declares Xylazine Emerging Threat
Policy

ONDCP designates fentanyl mixed with xylazine ('tranq') as emerging drug threat. The veterinary sedative, found in 30% of seized fentanyl, doesn't respond to naloxone and causes severe wounds.
July 11th, 2023
FDA Approves Over-the-Counter Naloxone
Policy

Narcan nasal spray approved for sale without prescription in pharmacies, convenience stores, and online. First OTC naloxone product in U.S. history, removing barrier to overdose reversal medication.
March 29th, 2023
X-Waiver Eliminated for Buprenorphine
Policy

Consolidated Appropriations Act removes requirement for special waiver to prescribe addiction treatment medication. Any provider with DEA Schedule III authority can now prescribe buprenorphine, expanding treatment access.
January 12th, 2023
Overdose Deaths Peak at 112,000
Milestone

Annual overdose deaths hit all-time high of 112,109 Americans—more than car accidents, gun violence, or any single disease for those under 45. Fentanyl involved in roughly 70% of deaths.
December 31st, 2022
China Imposes Class-Wide Fentanyl Controls
Policy

Under U.S. pressure, China schedules all fentanyl-related substances as controlled. Direct fentanyl shipments to U.S. largely cease, but precursor chemical trade to Mexican cartels continues.
May 1st, 2019
Wave Three: Synthetic Opioids Transform Crisis
Escalation

Illicitly manufactured fentanyl enters drug supply. Fifty times more potent than heroin, it causes deaths to accelerate dramatically. By 2017, synthetic opioids become leading driver of overdose deaths.
January 1st, 2013
Wave Two: Heroin Deaths Spike
Escalation

As prescription opioid restrictions tighten, users shift to cheaper heroin flooding in from Mexico. Heroin overdose rate increases fivefold between 2010 and 2016.
January 1st, 2010
Wave One Begins: Prescription Opioid Deaths Rise
Origin

CDC identifies start of opioid overdose epidemic, driven by aggressive marketing of OxyContin and other prescription painkillers. Deaths from prescription opioids begin steady climb that will continue for over two decades.
January 1st, 1999

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Predictions leaderboard

Deaths Continue Falling, Crisis Stabilizes Below 60,000 Annually

If current interventions maintain momentum—naloxone saturation, treatment access expansion, settlement funding deployment—deaths could fall below 60,000 by 2027, approaching pre-fentanyl levels. This requires sustained political commitment to harm reduction regardless of administration, continued China cooperation on precursors, and billions in settlement funds reaching frontline services rather than general budgets.

Discussed by: Drug Policy Alliance, Brookings Institution researchers, some public health officials

Consensus —

Decline Stalls as New Synthetic Threats Emerge

The slowing rate of decline in 2025 data may signal approaching plateau. Xylazine contamination continues rising—present in 75% of samples at some testing sites. Nitazenes, even more potent synthetic opioids, have appeared in isolated cases. If new adulterants spread or harm reduction funding contracts, progress could reverse. Regional disparities remain stark.

Discussed by: DEA analysts, Filter Magazine, harm reduction advocates

Consensus —

Policy Reversal Triggers Renewed Increase

The Trump administration's mixed signals on harm reduction—endorsing naloxone and test strips while emphasizing enforcement and opposing supervised consumption—could reduce funding for syringe services and community-based programs. If federal support contracts while settlement funds are diverted to non-evidence-based uses, deaths could climb again, particularly in underserved communities.

Discussed by: Georgetown O'Neill Institute, harm reduction organizations, some public health researchers

Consensus —

Racial Disparities Widen Even as Total Deaths Fall

Recent data shows overdose deaths falling faster among white Americans than Black, Hispanic, and Indigenous populations. If naloxone access and treatment expansion don't reach communities of color equitably, aggregate statistics could mask worsening crisis for specific populations. Baltimore 2024 data already shows concentration of deaths among older Black men increasing even as overall numbers decline.

Discussed by: JAMA Network Open researchers, Health Affairs analysts, Baltimore health officials

Consensus —

Historical Context

Portugal Drug Decriminalization (2001)

2001-present

What Happened

Facing Europe's worst heroin crisis—1% of the population addicted—Portugal decriminalized personal drug possession and redirected 90% of drug enforcement spending to health services. Police refer users to 'dissuasion commissions' offering voluntary treatment rather than arrest.

Outcome

Short Term

HIV infections from injection drug use dropped 90%. Overdose deaths fell from 80 per million to 6 per million by 2021—a 93% reduction.

Long Term

Portugal now has Europe's lowest overdose rate, one-fiftieth of the U.S. rate. The model influenced drug policy debates worldwide, though recent disinvestment has caused some backsliding.

Why It's Relevant Today

Portugal demonstrates that health-centered drug policy can produce sustained mortality reductions. The U.S. decline incorporates some elements—expanded treatment, harm reduction—but without decriminalization and with far less funding relative to need.

Crack Cocaine Epidemic Response (1980s-1990s)

1984-1997

What Happened

Crack cocaine spread rapidly through American cities, causing hospital emergencies to surge from 23,500 to 94,000 between 1984 and 1987. Congress responded with the Anti-Drug Abuse Act of 1986, creating 100:1 sentencing disparity between crack and powder cocaine.

Outcome

Short Term

Federal prison population for drug offenses exploded from 50,000 in 1980 to 400,000 by 1997. Black communities, comprising 80% of crack users, bore disproportionate impact.

Long Term

Mass incarceration devastated communities without reducing drug use. The punitive approach is now widely viewed as a failure, influencing current emphasis on treatment over imprisonment.

Why It's Relevant Today

The crack response shows consequences of treating addiction as primarily a criminal matter. The relative decline in opioid deaths coincides with policy shift toward public health approaches—though enforcement remains substantial, treatment and harm reduction now receive significant resources.

AIDS Crisis Harm Reduction (1980s-1990s)

1984-1996

What Happened

As HIV spread among injection drug users, activists pioneered needle exchange programs over fierce political opposition. First U.S. syringe exchange opened in Tacoma in 1988. Federal funding for such programs was banned from 1988 to 2016.

Outcome

Short Term

Cities with syringe exchanges saw HIV transmission among drug users drop by 50-80%. Programs also connected users to treatment and healthcare.

Long Term

Research established harm reduction as evidence-based public health. Federal funding ban lifted in 2016. By 2024, syringe services operate in most states and serve as distribution points for naloxone and fentanyl test strips.

Why It's Relevant Today

Current overdose decline builds on harm reduction infrastructure developed during AIDS crisis. Naloxone distribution often occurs through syringe services. The path from controversial intervention to mainstream policy took decades—fentanyl test strip legalization followed similar trajectory in compressed timeframe.